4-benzoyl-5-(4-bromophenyl)-1-(2-fluoro-4-(trifluoromethyl)benzyl)-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one | 1610600-05-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯啉
• 英文名称: 4-benzoyl-5-(4-bromophenyl)-1-(2-fluoro-4-(trifluoromethyl)benzyl)-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one
• CAS: 1610600-05-9
• 化学式: C₂₅H₁₆BrF₄NO₃
• 分子量: 534.305
• InChiKey: IIEKFYPKWNFNDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.39
• 重原子数：
  34.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  57.61
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  4-benzoyl-5-(4-bromophenyl)-1-(2-fluoro-4-(trifluoromethyl)benzyl)-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one 、 异丙醇 在 三苯基膦 、 偶氮二甲酸二异丙酯 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 以41%的产率得到4-benzoyl-5-(4-bromophenyl)-1-(2-fluorine-4-(trifluoromethyl)phenyl)-3-isopropoxy-1H-pyrrol-2(5H)-one
  参考文献：
  名称：

  Discovery of 1-arylpyrrolidone derivatives as potent p53–MDM2 inhibitors based on molecule fusing strategy

  摘要：

  Introducing an aryl moiety to our previous pyrrolidone scaffold by molecule fusing strategy afforded two sets of isopropylether-pyrrolidone and alpha-phenylethylamine-pyrrolidone derivatives. Two novel compounds 8b and 8g of the latter serial showed potent p53-MDM2 inhibitory activities with K-i values of 90 nM which were three-time higher than that of the parent compound. We also confirmed compound 8b can activate p53 proteins in lung cancer A549 cells. The results offered us valuable information for further lead optimization. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.04.063
• 作为产物：
  描述：

  2-氟-4-三氟甲基苄胺 、 2-Butenoic acid, 2-hydroxy-4-oxo-4-phenyl-, methyl ester, (2Z)- 、 对溴苯甲醛 以 1,4-二氧六环 为溶剂， 反应 12.17h， 生成 4-benzoyl-5-(4-bromophenyl)-1-(2-fluoro-4-(trifluoromethyl)benzyl)-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one
  参考文献：
  名称：

  Discovery of 1-arylpyrrolidone derivatives as potent p53–MDM2 inhibitors based on molecule fusing strategy

  摘要：

  Introducing an aryl moiety to our previous pyrrolidone scaffold by molecule fusing strategy afforded two sets of isopropylether-pyrrolidone and alpha-phenylethylamine-pyrrolidone derivatives. Two novel compounds 8b and 8g of the latter serial showed potent p53-MDM2 inhibitory activities with K-i values of 90 nM which were three-time higher than that of the parent compound. We also confirmed compound 8b can activate p53 proteins in lung cancer A549 cells. The results offered us valuable information for further lead optimization. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.04.063